It's Flu Season: What to Do if You Experience Shoulder Pain That Results From a Flu Vaccine

vaccine injury

The federal government provides money to individuals that experience shoulder pain or other injury following certain vaccinations.

WASHINGTON, DC, USA, November 30, 2016 / — Flu season is here, and that means millions of Americans are heading to doctors and pharmacists to obtain their annual flu shots. Although proven safe and effective for most people, in some instances being vaccinated with the annual flu vaccine can lead to serious complications, including shoulder pain which may become chronic.

This type of injury is known as Shoulder Injury Related to Vaccine Administration, (or "SIRVA"). A SIRVA injury can occur if a healthcare worker injects a vaccine at the wrong angle or too high up on the shoulder. Underweight patients or those with low body mass can also develop SIRVA if the needle is injected too deeply and over-penetrates the patient's deltoid muscle.

Frequent symptoms of SIRVA include pain at the injection site, stiffness, weakness, tingling, and loss of the shoulder's range of motion. Such injuries are often diagnosed as rotator cuff tears, bursitis, tendinitis, or adhesive capsulitis. In rare cases, surgery is required to correct the damage.

Fortunately, for those individuals who experience shoulder pain or injury, and seek treatment from a doctor, the Vaccine Injury Compensation Program is available to provide compensation, including an award for pain and suffering and lost wages. In addition to the flu vaccine, compensation is available for shoulder injuries caused by most other vaccines, including tetanus, Hepatitis A and B, and the HPV vaccine.

Enacted by Congress in 1986, the Vaccine Injury Compensation Program (also known as the vaccine court), is a federally funded, no fault compensation program, designed to provide monetary damages to people who have suffered a vaccine injury. Under the Vaccine Program, individuals can file a legal claim with the U.S. Court of Federal Claims. Special Masters from the court decide if a petitioner is eligible for compensation.

Although a majority of cases heard by the vaccine court are routinely settled, many people suffering from vaccine-related injuries fail to pursue recovery because of the perceived costs and difficulty associated with filing a complicated legal claim. Under the Vaccine Program, qualified vaccine attorneys are available and all costs for attorneys' fees are paid for by the vaccine court. This means that filing a claim for compensation should come at little or no financial cost to the injured party.

According to Vaccine Attorney Leah Durant, who specializes in representing individuals harmed by vaccines, many individuals find it difficult to obtain proper diagnosis and medical treatment following a vaccine injury.

"Often, people come to me after being told by a physician that it is impossible for severe shoulder injury to result following a needle injection, and many well-meaning healthcare providers are unaware of the damage that can result from the faulty administration of a vaccine," says Durant.

Since suffering her own shoulder injury related to vaccine administration, Durant has worked tirelessly to advocate for individuals diagnosed with SIRVA or other vaccine-related injuries. According to Durant, her personal experience with this type of injury helps her to relate to clients that experience the high level of pain and suffering associated with adverse vaccine reactions.

When deciding whether to pursue a claim for compensation for your vaccine shoulder injury, obtaining prompt and proper treatment is critical. For some, steroids and physical therapy may help promote recovery. Other more serious injuries may require costly surgical procedures and extensive treatment, physical therapy, or rehabilitation. Anyone who experiences severe shoulder pain shortly after a vaccination should seek immediate medical attention. This is important not only to obtain proper diagnosis and treatment, but to help support any future claim for compensation.

Because filing a claim for vaccine compensation involves complex legal and medical principles not found in traditional tort litigation, Durant recommends finding a vaccine attorney that focuses exclusively on vaccine litigation claims. Although claims are decided by the vaccine court in Washington, DC, vaccine attorneys can represent clients in all 50 states. This means clients are never required to travel to pursue their claims.

To further facilitate the process, leading firms such as the Law offices of Leah V. Durant employ medical professionals that can answer questions and provide valuable insight, often critical to a client's success.

"This is really about awareness for individuals who experience illness or injury following a flu shot or other vaccine," says Durant. "The vaccine court provides a means of help for injured parties, but it is important that people understand what symptoms to look for, and where to go to seek prompt medical treatment. At this point, most people are unaware of their rights or that compensation may be available. Our biggest challenge is making sure people are aware of the program and helping them to obtain the resources they need."

Carlo Chatman
Power PR
email us here

Source: EIN Presswire

recharj® Celebrates Grand Opening of Its Modern Meditation and Power Nap Studio in Downtown DC


recharj: power nap

recharj: meditation

recharj® Studio Offers Beginner to Advanced Meditation Classes and Power Naps

For businesses, we offer an invaluable path to boosting productivity and engagement. It is no coincidence that our first studio is in the nation’s capital.

— Daniel Turissini, Owner, recharj®

WASHINGTON, DC, USA, November 30, 2016 / — Type A White House staffers and lobbyists now have a new place to drop-in for a power nap or to meditate just steps away from 1600 Pennsylvania Ave. The DC studio offers a range of meditation traditions in class format for all levels as well as 25-minute power nap sessions. In addition to classes, recharj® offers private one-on-one instruction, self-guided digital content, as well as workshops and corporate mindfulness programs to provide clients with intensive practice opportunities.

The downtown DC-based wellness company, recharj®, has announced the official Grand Opening for December 15th, 2016 from 10:00 am – 2:00 pm at its flagship location, 1445 New York Ave NW. recharj®’s grand opening will consist of FREE classes, power nap demonstrations, raffles, a market with local food and health/wellness vendors, and the unveiling of a new sound healing experience.
“Washingtonians are feeling more stressed and fatigued than ever before. Our new studio offers a sanctuary to meditate, sip tea, power nap, and ‘recharj’,” said Christine Marcella, recharj®’s DC studio Manager. “In other words, it’s a space for people to reboot and sharpen their minds in preparation of their important work.”

“For businesses, we offer an invaluable path to boosting productivity and engagement,” founder Daniel Turissini comments. “It is no coincidence that our first studio is in the nation’s capital.”

The Washington, DC studio is home to a spacious, eco-therapeutic meditation and power nap room with a more intimate room for both private one-on-one and self-guided meditation. The space also features a range of amenities including private cubbies and kitchenette stocked with premium teas and other beverages. A full retail boutique will showcase men’s and women’s casualwear, as well as a variety of accessories to meet your mindfulness and lifestyle needs.

Clients who are new to recharj® will receive their first week free! A variety of package and membership options are also available.

recharj® – Washington, DC Studio
1445 New York Ave NW, Suite 130
Washington, DC 20005

About recharj®
recharj® strives to increase awareness and widespread adoption of meditation and power napping by making it accessible to all levels through a variety of traditions, convenient class times and a prime studio location. The company’s unique, diverse, and approachable style combines sound, light, nature, breath, and community to create a one-of-a-kind experience. recharj® meditation classes are taught by warm and skillful certified mindfulness instructors. In addition to meditation classes and power nap sessions, recharj® offers transformative Corporate Programs to empower business professionals to become more productive and advance their individual practice. recharj®’s beautiful, eco-therapeutic studios are built with sustainable practices in mind and leverages the latest technology. recharj® was founded in 2014 by Daniel J. Turissini. For more information, visit

Daniel Turissini
email us here

New business offers midday power naps

Source: EIN Presswire

Rediscover Yourself with New Look of Medical Tourism: Travcure

Medical Tourism in India

Rediscover Travcure

Travcure Medical Tourism announces the launch of a brand new, informative & much easier to navigate website for international patients.

NAGPUR, MAHARASHTRA, INDIA, November 30, 2016 / — Globalization of healthcare industry & growing demand for cost effective-high quality medical provisions in recent times has caught the attention of developing nations that have sufficient resources & potential to meet these demands of patients from all across the globe. Today, healthcare tourism has become a mainstream practice since a massive number of patients around the world are willing to cross borders in spite of common constraints like finance, language, difficulties in global travel & fear of unfamiliar places which are no longer acting as obstacles to medical tourists seeking healthcare treatment in foreign nations.

India has bloomed as a leading global medical tourism destination for patients around the world willing to travel beyond their native land seeking excellent quality of affordable healthcare. India features a vast pool of eminently specialized surgeons & healthcare professionals, many of whom have initially trained for decades in advanced western nations like United States, UK, Germany, & Canada before returning to their own country. In addition to this, availability of latest healthcare equipment & state-of-art facilities make India a strong contender for best medical tourism destination.

Travcure Medical Tourism is an internationally reputed medical service facilitator in India catering to a broad range of patients coming from every corner of the world. As a part of the growing Indian medical tourism success story, Travcure is established as the fastest growing healthcare tourism platform in South Asia. Optimal healthcare services offered by Travcure, in fact start with the first telephonic conversation when overseas patients call up to explain their health concerns. Travcure makes sure that their international guests get the best possible treatment & a hassle-free medical journey from the day they land in India to a successful departure following treatment.

International patients seeking highest quality treatments might be tempted to go to any extent of the earth to yield access to precise information that would help them lead a more productive & healthier life. They now have it at their fingertips on the best-ranking website for medical tourism in India which is managed by top healthcare experts in the country. The new look of the Travcure website has a cleaner & smoother design with improved functionality & enhanced rich content highly focused on their mission to cater to world-class medical services required by international patients.

Travcure Medical Tourism works on three basic principles – transparency in healthcare, clear communication & education. "Imagine a user-friendly portal where patients can easily understand & choose appropriate treatment plan for themselves" said Mr. Owais Saiyed, director of the Travcure Medical Tourism. International patients would be happy to use such a user-friendly site for obtaining stringent knowledge that will not only aid them to find the best suitable procedure & treatments they need, but also the best healthcare provisions they can afford. That is exactly what our new modified website aims to achieve & encourage through presentation of relevant & timely data which positively impacts the lives of our patients.

Travcure team is excited about the new website launch & the robust information it provides for their international guests. They believe that this website with a fresh look will allow online visitors to have a very informative experience as they continue to provide top-notch services to one & all. With a goal of offering visitors an easier way to learn, Travcure requests them to visit the new website & provide valuable suggestions & feedback to foster smoother interaction with patients.


Ayub Asad
Travcure Medical Tourism Consultants
email us here

Source: EIN Presswire

FDA EXCLUSIVE: A Spotlight on Regulation in Antibacterial Drug Development

Superbugs and Superdrugs 2017

FDA Division of Anti-Infective Products Director, Sumathi Nambair, due to Present at Superbugs & Superdrugs 2017

Networking and learning with our peers is the secret to improving the drug development pipeline.

— Joint statement from Transcript Partners and Chemical Biology Ventures

LONDON, ENGLAND, UNITED KINGDOM, November 30, 2016 / — SMi Group are thrilled to have industry expert Sumathi Nambair, provide regulatory and compliance updates on FDA legislation in antibacterial drug development at the 19th annual 2017 Superbugs & Superdrugs show, returning to Central London on 20th and 21st March.

The long running event will once again gather a global audience of scientific leaders, government bodies and anti-infective specialists, providing a focal point to discuss the global action plan on antimicrobial resistance.
In her current role at the FDA, Dr. Nambiar provides regulatory oversight for anti-infective products, including antibacterial, antifungal, and antiparasitic drugs. Her keynote presentation will explore FDA development programmes and activities to facilitate antibiotic drug discovery.

SMi Group are also delighted to welcome the expertise of Xavier Duportet, CEO from Eligo Bioscience who has recently confirmed to speak. Following a €2M deal from leading microbiome investor, Seventure, the talk will offer progressive insight into sequence-specific antimicrobials for targeted eradication of carriage.

The notable speaker line-up on at Superbugs & Superdrugs 2017 will also include:

Richard Bax, Senior Partner, TranScrip
Lloyd Czaplewski, Director, Chemical Biology Ventures
Chris Houchens, Branch Chief, BARDA
James Anderson, Head of Corporate Government Affairs, GlaxoSmithKline
Aileen Rubio, Head of Biology, Spero Therapeutics
David Williams, Chief Executive Officer, Discuva
Martin Everett, Chief Scientific Officer, ANTABIO SAS
Jean de Gunzburg, Scientific Director, Da Volterra
William J Weiss, Director, Pre-Clinical Services, UNT System College of Pharmacy

For those looking to attend there is currently a £400 saving available online ending on 30th November 2017. More information is available online at

Superbugs & Superdrugs 2017
20TH & 21ST March
Copthorne Tara Hotel, London, UK

–end –

Contact Information:

For all media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email:
For delegate inquiries contact Matthew Apps on Tel: +44 (0)20 7827 6093 / Email:
For exhibition and sponsorship inquiries contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email:

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Teri Arri
SMi Group
email us here

Source: EIN Presswire

Reusing Electronic Health Records Data for Clinical Research

Providing services for reusing electronic health records data for clinical research is profitable and sustainable in Europe

GENEVA, SWITZERLAND, November 30, 2016 / — The results of a new study published in the International Journal of Medical Informatics suggest that the exploitation of a new technological platform which enables the reuse of hospital-based electronic health records (EHR) data for clinical research appears profitable and sustainable for service providers in Europe. This innovative platform was developed by the Electronic Health Records for Clinical Research (EHR4CR) project funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), under the Innovative Medicines Initiative (IMI).

Dr Danielle Dupont, Chief Scientific Officer at Data Mining International, the independent research agency which has led this study, stated: “For the first time, using advanced simulation modelling, our study shows that the exploitation of the EHR4CR platform appears profitable and sustainable for service providers, in addition to generating added value and benefits for all stakeholders. These new operational solutions being scaled up across Europe, further robust value assessment studies are warranted in real-world settings.”

Professor Dr Georges De Moor, Head, Medical Informatics and Statistics Department, Ghent University, explained: “By reusing EHR data for clinical research, protocol feasibility assessments, patient identification for recruitment in clinical trials, and clinical data exchange can be processed much faster, and with greater precision. Resulting from the EHR4CR and other successful European Research and Development projects, the secure InSite® platform services are now being deployed. They will significantly enhance and speed up the conduct of clinical trials.”

Professor Dr Dipak Kalra, President of the European Institute for Innovation through Health Data (I~HD) added: “The EHR4CR platform will transform the clinical research landscape by enabling the re-use of hospital-based EHR patient-level data. Given the governing role of the I˷HD in this emerging multi-stakeholder ecosystem, EHR4CR and equivalent service providers will be well-positioned and supported to deliver trustworthy innovative solutions to facilitate and accelerate the conduct of clinical trials.”

Advanced financial simulations have established that the exploitation of EHR4CR solutions appears profitable and sustainable for EHR4CR service providers, in addition to generating substantial added value for clinical trials sponsors. This business model confirms that tangible benefits and value will be delivered by this new technological platform, to all clinical research stakeholders, in a sustainable manner.

Reference: Dupont D, Beresniak A, Sundgren M, Schmidt A, Ainsworth J, Coorevits P, Karla D, Dewispelaere M, De Moor G. Business analysis for a sustainable, multi-stakeholder ecosystem for leveraging the Electronic Health Records for Clinical Research (EHR4CR) platform in Europe. International Journal of Medical Informatics 2017 (97): 341–352.

About Data Mining International: Data Mining International SA is an independent international research agency based in Geneva (Switzerland). Data Mining International is specialized in public health, data mining, big data analytics, business modelling innovation, advanced simulation modelling for decision-making, risk assessment, multi-criteria analyses, health technology assessment, eHealth applications, and development and validation of quality of life instruments. Data Mining International brings innovative solutions to the public and private sectors, including pharmaceutical and biotech industries, foods and cosmetics, public health organizations, academia, and other interest groups, stakeholders and decision-makers, across geographic boundaries.

Alina Juusti-Hawkes
Data Mining International SA
email us here

Source: EIN Presswire

MEDraysintell will launch its Market Essentials reports

The “Market Essentials” reports aim to provide accurate facts in a condensed document with real added value for the reader.

LOUVAIN-LA-NEUVE AND LALAYE, BELGIUM AND FRANCE, November 30, 2016 / — MEDraysintell plans to launch early 2017 two new “Market Essentials Reports” providing key facts on Nuclear Medicine and Proton Therapy to advice non-industry insiders on the potential for investments, merger and acquisitions (M&A), technology and market development existing in healthcare technologies using radiation for diagnosis and therapy.

Those “Market Essentials” Reports will be real assets for the healthcare industry or for the financial community (investors, investment bankers and M&A professionals) to support their audit and to make informed decisions with unbiased and factual intelligence from experts.

The “Market Essentials” reports aim to provide accurate facts in a condensed document with real added value for the reader. These documents are also intended to take the opposing view of the many recent articles and market reports written by non-experts which are regrettably providing misleading, outdated or inaccurate information on nuclear medicine as well as in particle therapy. MEDraysintell identified recent publications reporting about confusing information on a new potential Molybdenum-99 shortage, or unrealistic projections for the PET versus SPECT market, while not recognizing the growth in radiotherapeutics too often erroneously associated with brachytherapy. For the proton therapy industry, several market reviews presented inaccurate facts such as data about the installed base or ignoring several major equipment vendors even mentioning companies not linked to the proton therapy market.

The “Nuclear Medicine Market Essentials” and the “Proton Therapy Market Essentials” reports will include important insights on the market, key drivers, vendors, products of interest for the coming decade, as well as companies to monitor, mostly in tabulated forms with the most recent and precise figures and names.

MEDraysintell believes it is the right moment to publish such “Market Essentials” reports as both the nuclear medicine and proton therapy have entered an era of high potential for growth, involving new technologies and a high number of products close to being marketed or under advanced stage development. This business will trigger the interest of new investors as well as the conventional pharmaceutical industry to support these markets which are rising up to three times faster than the global healthcare market.

MEDraysintell has already supported numerous companies globally helping them to better understand these markets, and welcomes your requests for specific intelligence needs in these areas.

About MEDraysintell
Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy.

We offer the most comprehensive set of reports and directories, with over 1,800 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories.

MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare.

Paul-Emmanuel Goethals and Richard Zimmermann
+32 491 080 968 and +33 6 82 80 06 00
email us here

Source: EIN Presswire

Acino closes the deal to divest its patch business to Luye Pharma Group Ltd.

Acino closed the deal with Luye Pharma Group Ltd. to sell Acino's transdermal patch and implant business.

The divestment allows us to focus on growth in our key markets. We believe that Luye’s vision and strategy will further the expansion of the existing R&D and manufacturing capabilities in Miesbach.

— Kalle Känd, CEO Acino

ZURICH, SWITZERLAND, November 30, 2016 / — On November 30, 2016, Acino International AG and Acino Pharma AG (together “Acino”) closed the deal with Luye Pharma Group Ltd. (“Luye”), which they announced on July 25, 2016, to sell Acino’s transdermal patch and implant businesses. The divestment includes Acino’s transdermal manufacturing operations in Miesbach, Germany, distribution, and R&D capabilities.

The divestment is in line with Acino’s strategy of shaping the organization for growth in emerging markets and further expanding Acino’s regional commercial presence in its key markets of the Middle East and Africa, the CIS region, and Latin America.

The divestment allows us to focus on growth in our key markets, and we believe that Luye’s vision and strategy will further the expansion of the existing R&D and manufacturing capabilities in Miesbach. An R&D focused company like Luye will be able to leverage the high potential of our transdermal business in the best possible way in the future, including further global expansion”, says Kalle Känd, CEO at Acino.

Acino retains the marketing rights to certain transdermal patches in its strategic emerging markets.

Ulrike Seminati
Acino International AG
+41 44 555 2203
email us here

Source: EIN Presswire

Targeting Cancer with Emerging Antisense Oligonucleotide Drugs and Nano Medicines. Clinical Results Unveiled at RNA 2017

RNA Therapeutics 2017

RNA Therapeutics returns to Central London on 22nd & 23rd February 2017 featuring a spotlight on RNA used to in Cancer therapy

For cancer diseases, RNAi will provide the specificity that was missed by standard chemotherapy, immune-oncology will supress immune resistance

— Silenseed

LONDON, ENGLAND, UNITED KINGDOM, November 30, 2016 / — Due to significant investment and promising results in early phase clinical trials for chronic and rare diseases, reports have predicted the DNA and RNA therapeutics market to reach $1.2 billion by 2020. Of the 700 DNA and RNA therapeutics that are in the drug development pipeline, nearly 35% are targeting oncology.* Source

Hear more on cancer therapeutics next February when SMi’s 8TH annual 2017 conference on RNA Therapeutics returns to London.

Featured presentations include:


Heinrich Haas, RNA Formulation and Drug Development Vice President at BioNTech AG will provide new updates on the development of nucleic acid based nanomedicines. The talk will explore mRNA for cancer vaccination with detailed insight into formulation development and preclinical proof-of concept for RNA-lipoplex formulations. GMP manufacturing and clinical testing of RNA-lipoplex products will also be discussed.


A big pharma update on clinical trials in oncology as Mark Edbrooke, Senior Principal Scientist from AstraZeneca, looks at the progress of emerging antisense oligonucleotide drugs and drug delivery methods to target "un-druggable" sites.


Hear how BioNTech are driving progress in cancer immunotherapy through case study results into the first clinical experience with mRNAs in individualised cancer immunotherapy. Vice President for RNA Biochemistry & Manufacturing, Andreas Kuhn, will give insight into key topics surrounding: the optimisation of mRNA for therapeutic applications; GMP manufacturing of mRNA; and the IVAC MUTANOME concept.

Further information is available online at

8th Annual Event: RNA Therapeutics 2017
Conference: 22nd & 23rd Feb | Interactive workshop: 21st Feb
Copthorne Tara Hotel, Kensington, London, UK

— end —

Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email:
To register for the conference, visit or contact Fateja Begum on
Tel: +44 (0)20 7827 6184 / Email:
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 /

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Teri Arri
SMi Group
email us here

Source: EIN Presswire

Introducing Ziwira Inc: Canada’s newest hub for everything organic, eco-friendly and all natural

Ziwira Store – organic, all-natural and eco-friendly shopping

Ziwira – Live consiously

Shopping organic has never been easier – your shopping cart at Ziwira is non-toxic, GMO-free, no artificial colours, flavours, preservatives & 100% organic

TORONTO, ONTARIO, CANADA, November 29, 2016 / — Toronto, ON – After a year in the works, Ziwira Inc., a Toronto-based environmentally friendly and green living online store, has officially launched their website located at With access to thousands of eco-friendly and organic products, Ziwira customers are reducing their carbon footprint, one click at a time. They have successfully established a rare vision to connect the growing market of environmentally conscious Canadians to the most trusted green brands through the Ziwira online platforms.

With over two-thousand products stemming across five different categories (Health & Beauty, Mom & Baby, Organic Food, Supplements & Vitamins and Home), Canadians can rest assure that everything they place in their shopping cart is all-natural, sustainable and environmentally safe. Shopping green has never been easier – your shopping cart will always be non-toxic, GMO-free, and never contain artificial colors, flavors, preservatives or irradiated ingredients.

Ziwira is dedicated to providing the best of the best in gluten-free, all-natural and vegan friendly options in food, biodegradable and non-toxic makeup and beauty products, vitamins and minerals, and environmentally safe cleaning supplies. They continue to grow their available products by specializing in free listings for merchants. With over 30 positively green companies (From big brands like Now Foods, Organika, Prairie Naturals, Waleda, Jamieson, Attitude, Inari and Ddrop Company, to product specific companies such as Just Juice) Ziwira store connects like-minded companies with their customers.

What separates Ziwira from other green e-commerce websites in the online shopping industry, is that Ziwira provides a 100% satisfaction guaranteed by providing free returns and exchanges, express delivery all across Canada through Purilator and the lowest prices guaranteed. It’s a shopping experience like no other and establishes a level of trust and comfort with their customers by taking the guess work out of shopping green. There’s no need to shop around for the best price when Ziwira has it already. Passionate about our planet and dedicated to making a difference, you can learn more about this publicly listed company by visiting Nasdaq.

Ziwira Inc.
email us here

Source: EIN Presswire

Launch Leads Ranks #94 of the Utah 100 Fastest Growing Companies of 2016

B2B Lead Generation is in high demand nationwide as businesses look to shorten sales cycles

SALT LAKE CITY , UTAH, USA, November 28, 2016 / — Launch Leads ( was ranked the 94th 2016 fastest growing company in Utah by MountainWest Capital Network (MWCN) ( at the 22nd annual Utah 100 Awards Program. The annual program recognizes the 100 fastest growing Utah companies, the Top Revenue Growth companies, and the "Emerging Elite" companies.

"Launch Leads' continued growth is very exciting. Internally we have dedicated a massive amount of resources to improving all facets of our organization and we're seeing positive results. Our process improvements and strategic hires continue to drive industry leading performance which translates into a positive ROI for our clients. Our amazing employees continue to be our greatest asset and we remain dedicated to their ongoing development," said Scott Smith, CEO of Launch Leads.

The 100 fastest growing companies in Utah are selected from thousands of eligible applicants throughout the state and represent a cross-section from all industries.

For more information please visit: or call (877) 466-0111

Scott Smith
Launch Leads
(877) 466-0111
email us here

Source: EIN Presswire